These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21908577)

  • 41. Prognostic and predictive significance of nuclear HIF1α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab.
    Patel U; Pandey M; Kannan S; Samant TA; Gera P; Mittal N; Rane S; Patil A; Noronha V; Joshi A; Patil VM; Prabhash K; Mahimkar MB
    Br J Cancer; 2020 Dec; 123(12):1757-1766. PubMed ID: 32939054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base.
    Amini A; Jones BL; McDermott JD; Serracino HS; Jimeno A; Raben D; Ghosh D; Bowles DW; Karam SD
    Cancer; 2016 May; 122(10):1533-43. PubMed ID: 26969811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression.
    Alterio D; Marvaso G; Maffini F; Gandini S; Chiocca S; Ferrari A; Preda L; Rocca MC; Lepanto D; Fodor C; Volpe S; Dicuonzo S; Laudati A; Giugliano G; Ansarin M; Jereczek-Fossa BA
    Med Oncol; 2017 Jun; 34(6):107. PubMed ID: 28452036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
    Zhou C; Shen Z; Ye D; Li Q; Deng H; Liu H; Li J
    Cell Physiol Biochem; 2018; 50(3):868-882. PubMed ID: 30355925
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
    Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
    Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Associated risk of XRCC1 and XPD cross talk and life style factors in progression of head and neck cancer in north Indian population.
    Kumar A; Pant MC; Singh HS; Khandelwal S
    Mutat Res; 2012 Jan; 729(1-2):24-34. PubMed ID: 21945240
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
    Fakhry C; Westra WH; Li S; Cmelak A; Ridge JA; Pinto H; Forastiere A; Gillison ML
    J Natl Cancer Inst; 2008 Feb; 100(4):261-9. PubMed ID: 18270337
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.
    Nyflot MJ; Kruser TJ; Traynor AM; Khuntia D; Yang DT; Hartig GK; McCulloch TM; Wiederholt PA; Gentry LR; Hoang T; Jeraj R; Harari PM
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):942-51. PubMed ID: 25659884
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.
    Pajares B; Trigo JM; Toledo MD; Álvarez M; González-Hermoso C; Rueda A; Medina JA; de Luque V; Jerez JM; Alba E
    BMC Cancer; 2013 Jan; 13():26. PubMed ID: 23331666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST.
    Katsuura T; Kitajima K; Fujiwara M; Terada T; Uwa N; Noguchi K; Doi H; Tamaki Y; Yoshida R; Tsuchitani T; Fujita M; Yamakado K
    Ann Nucl Med; 2018 Aug; 32(7):453-462. PubMed ID: 29858797
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Histological assessment of cervical lymph node identifies patients with head and neck squamous cell carcinoma (HNSCC): who would benefit from chemoradiation after surgery?
    Wan XC; Egloff AM; Johnson J
    Laryngoscope; 2012 Dec; 122(12):2712-22. PubMed ID: 23060119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant Chemoradiation After Surgical Resection in Elderly Patients With High-Risk Squamous Cell Carcinoma of the Head and Neck: A National Cancer Database Analysis.
    Woody NM; Ward MC; Koyfman SA; Reddy CA; Geiger J; Joshi N; Burkey B; Scharpf J; Lamarre E; Prendes B; Adelstein DJ
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):784-792. PubMed ID: 28602410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elevated expression of iASPP in head and neck squamous cell carcinoma and its clinical significance.
    Liu Z; Zhang X; Huang D; Liu Y; Zhang X; Liu L; Li G; Dai Y; Tan H; Xiao J; Tian Y
    Med Oncol; 2012 Dec; 29(5):3381-8. PubMed ID: 22815155
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
    Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
    Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Salvage Surgery for Recurrence after Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.
    Elbers JBW; Al-Mamgani A; van den Brekel MWM; Jóźwiak K; de Boer JP; Lohuis PJFM; Willems SM; Verheij M; Zuur CL
    Otolaryngol Head Neck Surg; 2019 Jun; 160(6):1023-1033. PubMed ID: 30526317
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.
    Namazie A; Alavi S; Olopade OI; Pauletti G; Aghamohammadi N; Aghamohammadi M; Gornbein JA; Calcaterra TC; Slamon DJ; Wang MB; Srivatsan ES
    Laryngoscope; 2002 Mar; 112(3):472-81. PubMed ID: 12148857
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Association of the expression of p53 and p16INK4A with the clinical and morphological characteristicsof patients with head and neck squamous cell cancer].
    Stukan AI; Chukhray OY; Porkhanov VA; Bodnya VN
    Arkh Patol; 2019; 81(3):12-18. PubMed ID: 31317926
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-grade acute organ toxicity and p16(INK4A) expression as positive prognostic factors in primary radio(chemo)therapy for patients with head and neck squamous cell carcinoma.
    Tehrany N; Kitz J; Rave-Fränk M; Lorenzen S; Li L; Küffer S; Hess CF; Burfeind P; Reichardt HM; Canis M; Beissbarth T; Wolff HA
    Strahlenther Onkol; 2015 Jul; 191(7):566-72. PubMed ID: 25575976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma.
    Skillington SA; Kallogjeri D; Lewis JS; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2017 Mar; 143(3):253-259. PubMed ID: 27918781
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HPV DNA in saliva from patients with SCC of the head and neck is specific for p16-positive oropharyngeal tumours.
    Wasserman JK; Rourke R; Purgina B; Caulley L; Dimitroulakos J; Corsten M; Johnson-Obaseki S
    J Otolaryngol Head Neck Surg; 2017 Jan; 46(1):3. PubMed ID: 28061890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.